NaV1.8 Pain Signal Inhibitor VX-993 Fails to Show Efficacy in Phase 2 Trial of Acute Pain
Written by
Neurology Live
Published
0
comments
0
min
Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.